Remember our old friends Liveyon? Their leader John Kosolcharoen? Liveyon’s continuing metamorphosis This biologics supply firm has gone through several stages of corporate metamorphosis as a supplier of biologics including at first a purported living umbilical cord stem cell product. That stem cell thrust ultimately landed a dozen or more people in the hospital as […]
Liveyon is back (again) with unproven exosome product Read More »
The novel coronavirus and the disease it causes, COVID-19, have swept the world with few proven treatment options. Vaccines are only recently being rolled out the last 2 or so months, which gives some real hope. While the novel coronavirus-caused illness is generally a mild disease in kids (many of whom don’t even show symptoms),
The Niche COVID-19 updates & resources Read More »
It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as
Regenerative medicine recommended reads including $191 million to researcher Read More »
Making a CRISPR baby is a controversial idea to even propose now for many reasons, yet even after He Jiankui’s train wreck some people have seemed eager to try it including apparently a scientist whose name perhaps many readers here are not so familiar with in this context: Professor Hui Yang. ‘CRISPR baby guys’ Is
Heads up on Hui Yang, another potential aspiring CRISPR baby researcher Read More »
Umbilical “stem cell” supplier Liveyon has suspended sales of its products according to the WaPo after a harsh FDA warning letter. While not fully shutting off the tap to the perinatal stem cell clinic universe, as other suppliers including in Utah seem to be continuing, this Liveyon voluntary hold will equal a major reduction in
Why did clinic supplier Liveyon halt sales but others kept going despite FDA? Read More »
Washington Post reporters William Wan and Laurie McGinley have a new piece on the unproven regenerative clinic firm the Lung Health Institute. This article has a number of surprises and new insights. Previously the Lung Health Institute was called just the Lung Institute. It was recently acquired by the publicly-traded company H-CYTE, stock symbol HCYT. In the
‘I’d need a drink’: WaPo deep dive on clinic firm Lung Health Institute Read More »
Once upon a time this blog and major outlets around the world were regularly writing about a Japanese stem cell researcher named Haruko Obokata (小保方 晴子). Whatever happened to Obokata and the other folks directly involved in STAP cell research? First, a bit of background because maybe still a few people never heard of STAP cells
Whatever happened to the STAP cell scientists including Haruko Obokata? Read More »
Today’s post is a review of Unnatural Selection, the new Netflix science docuseries focused on CRISPR and other disruptive genetic and reproductive technologies. The show is an interesting mix of personalities and stories from patients, scientists, biohackers, and more. One patient thread is the story of a wonderful little boy named Jackson Kennedy. He wants
Unnatural Selection review: captivating mind-bender but needed more science Read More »
There appears to be a big, risky loophole in the relatively new national Right To Try law. Some folks apparently anticipated this problem long ago, but I think most of us weren’t aware of it. Update: More specifically, some law and policy experts were writing about this and other potential loopholes in 2018. I recommend
Right To Try law has a big loophole that’s an opening for bad actors Read More »
ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the
ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »